KR100905453B1 - 활성성분의 제어 용해 - Google Patents

활성성분의 제어 용해 Download PDF

Info

Publication number
KR100905453B1
KR100905453B1 KR1020020018458A KR20020018458A KR100905453B1 KR 100905453 B1 KR100905453 B1 KR 100905453B1 KR 1020020018458 A KR1020020018458 A KR 1020020018458A KR 20020018458 A KR20020018458 A KR 20020018458A KR 100905453 B1 KR100905453 B1 KR 100905453B1
Authority
KR
South Korea
Prior art keywords
ion exchange
active ingredient
exchange resin
resin
meq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020020018458A
Other languages
English (en)
Korean (ko)
Other versions
KR20020079473A (ko
Inventor
휴거스린
벨라미사이몬앤드류
한크리스티나
Original Assignee
롬 앤드 하스 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 롬 앤드 하스 캄파니 filed Critical 롬 앤드 하스 캄파니
Publication of KR20020079473A publication Critical patent/KR20020079473A/ko
Application granted granted Critical
Publication of KR100905453B1 publication Critical patent/KR100905453B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020020018458A 2001-04-09 2002-04-04 활성성분의 제어 용해 Expired - Lifetime KR100905453B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28244301P 2001-04-09 2001-04-09
US60/282,443 2001-04-09

Publications (2)

Publication Number Publication Date
KR20020079473A KR20020079473A (ko) 2002-10-19
KR100905453B1 true KR100905453B1 (ko) 2009-07-02

Family

ID=23081541

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020020018458A Expired - Lifetime KR100905453B1 (ko) 2001-04-09 2002-04-04 활성성분의 제어 용해

Country Status (6)

Country Link
US (1) US7153497B2 (enExample)
EP (1) EP1250937B1 (enExample)
JP (1) JP4295951B2 (enExample)
KR (1) KR100905453B1 (enExample)
DE (1) DE60232290D1 (enExample)
TW (1) TWI242446B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
WO2006101536A1 (en) * 2004-11-04 2006-09-28 Akina, Inc. Fast-melting tablets having taste-masking and sustained release properties
EP2018160B1 (en) 2006-03-16 2011-12-14 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
US8187636B2 (en) 2006-09-25 2012-05-29 Atlantic Pharmaceuticals, Inc. Dosage forms for tamper prone therapeutic agents
CA2689101C (en) * 2007-05-30 2013-01-22 Neos Therapeutics, Lp Modifying drug release in suspensions of ionic resin systems
FR2947276B1 (fr) * 2009-06-24 2012-10-26 Seppic Sa Composition cosmetique a base de resines echangeuses d'ions chargees avec des lipoaminoacides
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
EP2725072B1 (en) 2012-10-25 2015-07-22 Rohm and Haas Company Aldehyde abatement with porous amine functional resins
US8999393B1 (en) 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US11505716B2 (en) 2017-07-11 2022-11-22 Dow Global Technologies Llc Aqueous dispersion and aqueous coating composition comprising the same
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510128A (en) * 1983-01-12 1985-04-09 Ciba Geigy Corporation Resinate of a substituted carboxylic acid, the preparation and use thereof, and pharmaceutical compositions containing it

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1585174A (en) * 1976-06-16 1981-02-25 Ici Ltd Separation of sugars from mixtures
US4898729A (en) * 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
GB9005498D0 (en) * 1990-03-12 1990-05-09 Beecham Group Plc Composition
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510128A (en) * 1983-01-12 1985-04-09 Ciba Geigy Corporation Resinate of a substituted carboxylic acid, the preparation and use thereof, and pharmaceutical compositions containing it

Also Published As

Publication number Publication date
KR20020079473A (ko) 2002-10-19
US7153497B2 (en) 2006-12-26
US20020146384A1 (en) 2002-10-10
EP1250937A2 (en) 2002-10-23
JP4295951B2 (ja) 2009-07-15
TWI242446B (en) 2005-11-01
EP1250937B1 (en) 2009-05-13
DE60232290D1 (de) 2009-06-25
JP2003012562A (ja) 2003-01-15
EP1250937A3 (en) 2003-09-24

Similar Documents

Publication Publication Date Title
KR100905453B1 (ko) 활성성분의 제어 용해
ES2378573T3 (es) Formulaciones de liberación modificada que contienen complejos de fármaco-resina de intercambio iónico
US11337919B2 (en) Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release
Guo et al. Ion-exchange resins as drug delivery carriers
RU2256442C2 (ru) Потребляемая пленка, предназначенная для держания во рту, и способ получения потребляемой пленки
RS59061B1 (sr) Farmaceutska kompozicija
TR201815803T4 (tr) Bir aktif ajan, gliserin ve sorbitol içeren sıvı formülasyonlar.
Arafat Approaches to achieve an oral controlled release drug delivery system using polymers: a recent review
Elder Pharmaceutical applications of ion-exchange resins
US20060134148A1 (en) Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
US20050013792A1 (en) Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
Venkatesh Formulation of taste masked oro-dispersible tablets of ambroxol hydrochloride
US20020176842A1 (en) Extended release of active ingredients
Pisal et al. Drug release properties of polyethylene-glycol-treated ciprofloxacin-Indion 234 complexes
JP2008546835A (ja) 複数の活性薬物−樹脂抱合体
US20230310646A1 (en) Salt responsive nanogels and nanoparticles
EP2361611A2 (en) Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
JP3207495B2 (ja) 安定した放出性を有する徐放性懸濁製剤
Dugad et al. Ion exchange resins: An novel approach towards taste masking of bitter drugs and sustained release formulations with their patents
El-Hamid et al. An ion pairing approach to enhance oral bioavailability of alendronate
Muzammil et al. Ion Exchange Resins for Clinical Applications
US20190183817A1 (en) Extended release suspensions of mixtures of dextro- and levo-amphetamines

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20020404

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070404

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 20020404

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20080421

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20080929

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20090323

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20090624

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20090625

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20120611

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20130604

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20130604

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20140609

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20140609

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20150602

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20150602

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20160527

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20160527

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20170601

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20170601

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20180529

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20180529

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20190530

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20190530

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20210527

Start annual number: 13

End annual number: 13

PC1801 Expiration of term

Termination date: 20221004

Termination category: Expiration of duration